InMode Ltd. (Nasdaq: INMD ), a leading global provider of innovative medical technologies, announced today that it will release its financial results for the third quarter 2020 before the Nasdaq market opens on T
|
YOKNEAM, Israel, Oct. 13, 2020 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, announced today that it will release its financial results for the third quarter 2020 before the Nasdaq market opens on Thursday, November 12, 2020.
 InMode is currently finalizing its financial results for the three months ended September 30, 2020. While complete financial information and operating data are not yet available, set forth below are certain preliminary results of InMode’s financial results for such period, subject to final adjustments and other developments that may arise between now and the time such financial results are finalized. Based on preliminary results, management expects:
[1] Please refer to “Use of Non-GAAP Financial Measure” below for important information about non-GAAP financial measures. Non-GAAP financial results exclude stock-based compensation and related tax adjustments. “InMode has proven once again that its two main electro-surgical proprietary and unique technologies; minimally invasive and hands-free, are becoming the gold standard of the minimally invasive surgical procedures for a variety of medical indications,” commented Moshe Mizrahy, InMode’s CEO. “We expect the underlying interest in our differentiated product suite will continue to drive sales into the fourth quarter of 2020. As a result, we decided to increase our full year 2020 revenue guidance to $192-$195 million.” Members of InMode’s management team will host a conference call to discuss the third quarter 2020 financial results on November 12, 2020, at 8:30 a.m. Eastern Time. The presenters include Mr. Moshe Mizrahy, Chairman and Chief Executive Officer; Dr. Michael Kreindel, co-founder and Chief Technology Officer; Mr. Yair Malca, Chief Financial Officer; Mr. Shakil Lakhani, President of North America; and Dr. Spero Theodorou, Chief Medical Officer. The Company encourages participants to pre-register for the conference call using the following link: https://dpregister.com/sreg/10148536/da3e5e2fe8. Callers will receive a unique dial-in upon registration, which enables immediate access on the day of the call. Participants may pre-register at any time, including up to and after the call start time. For callers that opt out of pre-registration, please dial one of the following teleconferencing numbers. Please begin by placing your call ten minutes before the conference call commences. If you are unable to connect using the toll-free number, please try the international dial-in number. U.S. Toll-Free: 1-866-777-2509 The conference call will also be webcast live from a link on InMode’s website at https://inmodemd.com/investors/events-presentations/. A replay of the conference call will be available from November 12, 2020 at 12:00 p.m. Eastern Time to November 26, 2020 at 11:59 p.m. Eastern Time. To access the replay, please dial one of the following numbers: Replay U.S. TOLL-FREE: 1-877-344-7529 A replay will also be available for 90 days on InMode’s website at https://inmodemd.com/investors/events-presentations/ About InMode InMode is a leading global provider of innovative medical technologies. InMode develops, manufactures, and markets devices harnessing novel radiofrequency (“RF”) technology. InMode strives to enable new emerging surgical procedures as well as improve existing treatments. InMode has leveraged its medically accepted minimally-invasive RF technologies to offer a comprehensive line of products across several categories for plastic surgery, gynecology, dermatology, otolaryngology, and ophthalmology. For more information about InMode, please visit www.inmodemd.com. Use of Non-GAAP Financial Measure This release includes an estimate of InMode’s expected non-GAAP earnings per diluted share for the third quarter 2020. Because this financial measure is used in InMode’s internal analysis of financial and operating performance, management believes that it provides greater transparency to investors of management’s view of InMode’s economic performance. Management also believes the presentation of this measure allows investors to more effectively evaluate and compare the performance of InMode to that of its peers, although InMode’s presentation of this non-GAAP measure may not be comparable to other similarly-titled measures of other companies. InMode has not provided a reconciliation of non-GAAP earnings per diluted share to the corresponding GAAP financial measure on a forward-looking basis due to the potential variability, limited visibility and unpredictability. See “Forward-Looking Statements” for additional information. Forward-Looking Statements This press release contains certain forward-looking statements. Words such as “expects” and “strives” or similar expressions are intended to identify forward-looking statements. These forward-looking statements are subject to the inherent uncertainties in predicting future results and conditions, many of which are beyond the control of InMode, including, without limitation, risks relating to the impact of the COVID-19 outbreak and the risk factors and other matters set forth in its Annual Report on Form F-20 for the year ended December 31, 2019 filed with the Securities and Exchange Commission on February 18, 2020. The COVID-19 outbreak has caused significant volatility and disruption in the financial markets both globally and in the United States. If COVID-19 continues to spread or the response to contain it is unsuccessful, InMode could experience material adverse effects on its business, financial condition, liquidity and results of operations. InMode undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law. Investor Relations Contact: Miri Segal-Scharia
SOURCE InMode Ltd. | ||
Company Codes: NASDAQ-NMS:INMD |
View original content:
